SCHEDULE: FMR LLC Discloses 11.7% Stake in Lexicon Pharmaceuticals

FMR LLC, through its subsidiaries, has reported beneficial ownership of 11.7% of Lexicon Pharmaceuticals Inc.'s common stock as of June 30, 2026.

Summary

• FMR LLC, along with Abigail P. Johnson and other affiliated entities, has filed a Schedule 13G, indicating their beneficial ownership of Lexicon Pharmaceuticals Inc. common stock.
• The filing, dated June 30, 2026, shows a total of 51,782,044.66 shares owned, representing 11.7% of the class.
• Fidelity Growth Company Commingled Pool holds a significant portion, 24,673,450.00 shares (5.6%), of this total.
• The filing is an amendment (Amendment No. 4) to a previous filing.
• FMR LLC is classified as a holding company (HC), and Abigail P. Johnson is classified as an insider (IN).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily reflecting routine ownership updates rather than significant company performance changes.

Positives

• Significant institutional ownership by FMR LLC indicates confidence in Lexicon Pharmaceuticals' long-term prospects.
• The filing confirms a substantial and stable ownership stake, which can be viewed positively by the market.

Negatives

• The filing itself does not contain performance data or strategic updates, making it difficult to assess company performance directly.
• The nature of a 13G filing is primarily informational regarding ownership, not an indicator of company operational success or failure.

Risks

• Potential for future changes in FMR LLC's ownership stake, which could impact share price and liquidity.
• The filing does not provide details on the strategy behind this ownership, leaving room for speculation.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Lexicon Pharmaceuticals' future performance. It solely reports on ownership.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that large institutional filings like this Schedule 13G are common in the pharmaceutical sector, reflecting significant investment by asset managers in companies with potential for growth or therapeutic breakthroughs. The 11.7% stake by FMR LLC is substantial and positions them as a key stakeholder.

Stakeholder Impact

• Shareholders: The substantial stake held by FMR LLC may provide a degree of stability to the stock, but also indicates a significant influence by a large institutional investor.
• Management: Lexicon Pharmaceuticals' management will need to consider the interests of FMR LLC as a major shareholder.
• Creditors: Stable institutional ownership can be viewed positively by creditors as it may indicate a more stable financial outlook for the company.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to hold their beneficial ownership of Lexicon Pharmaceuticals Inc. common stock.
• Future filings will be made if there are material changes in ownership.

Key Dates

Keywords

Lexicon Pharmaceuticals, FMR LLC, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Ownership Stake, Fidelity